scispace - formally typeset
B

B. Jahn-Schmid

Researcher at University of Vienna

Publications -  18
Citations -  1563

B. Jahn-Schmid is an academic researcher from University of Vienna. The author has contributed to research in topics: T cell & Epitope. The author has an hindex of 14, co-authored 18 publications receiving 1520 citations. Previous affiliations of B. Jahn-Schmid include University of Agricultural Sciences, Dharwad & University of Natural Resources and Life Sciences, Vienna.

Papers
More filters
Journal ArticleDOI

Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy

TL;DR: Evaluated by site‐directed mutagenesis the contributions of individual amino acid residues/positions for IgE binding to Bet v 1, the major allergen of birch pollen, and found that IgEbinding toBet v 1 depended on at least six amino acid sequences, but conserved T cell activating capacity is necessary for immunomodulation.
Journal ArticleDOI

Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-gamma production in cells from allergic individuals and inhibit IgE synthesis in vitro.

TL;DR: The data suggest that CpG‐ODN display a strong influence on the ongoing immune response and might represent potential adjuvants for specific immunotherapy of type I allergy.
Journal ArticleDOI

IgE-mediated immediate-type hypersensitivity to the pyrazolone drug propyphenazone

TL;DR: In this paper, a novel ELISA system was developed to unequivocally demonstrate that IgE-mediated Type I allergy is the main mechanism leading to immediate-type adverse reactions to the analgesic drug PP.
Journal ArticleDOI

Allergen microarray: comparison of microarray using recombinant allergens with conventional diagnostic methods to detect allergen-specific serum immunoglobulin E.

TL;DR: A novel test system for the detection of allergen‐specific IgE and recent advances in biochip technology led to the development of this test system.
Journal ArticleDOI

Art v 1, the major allergen of mugwort pollen, is a modular glycoprotein with a defensin-like and a hydroxyproline-rich domain

TL;DR: Re recombinant nonglycosylated Art v 1 is a good starting template for engineering hypoallergenic vaccines for weed‐pollen therapy and the involvement of the defensin fold and posttranslational modifications in the formation of epitopes recognized by IgE antibodies from allergic patients was revealed.